mRNA delivery of mosaic-8 pan-sarbecovirus RBD vaccines elicits distinct antibody epitope signatures
Authors:
- Alexander A. CohenACAlexander A. Cohen
- Jennifer R. KeeffeJKJennifer R. Keeffe
- Indeever MadireddyIMIndeever Madireddy
- Ange-Célia I. Priso FilsAFAnge-Célia I. Priso Fils
- Kim-Marie A. DamKDKim-Marie A. Dam
- Rory A. HillsRHRory A. Hills
- Woohyun J. MoonWMWoohyun J. Moon
- Mark R. HowarthMHMark R. Howarth
- Magnus A.G. HoffmannMHMagnus A.G. Hoffmann
Preprint
Abstract
Effective pan-sarbecovirus vaccines could prevent future zoonotic spillovers of SARS-like betacoronaviruses. We previously developed protein-based mosaic-8 nanoparticles displaying eight diverse sarbecovirus RBDs, either individually (mosaic-8 RBD-NPs) or as two “quartets” of four tandemly-arranged RBDs (dual-quartet RBD-NPs), which elicited broadly cross-reactive antibodies but require multi-component manufacturing. Here, we address scalability challenges by extending the mosaic-8 concept to mRNA by encoding membrane-bound RBD quartets as dual-quartet RBD-mRNA and dual-quartet RBD-EABR-mRNA, the latter leveraging ESCRT- and ALIX-binding region (EABR) technology for immunogen display on cell surfaces and secreted virus-like particles. Compared with protein-based mosaic-8 immunogens, mRNA-encoded mosaic-8 vaccines induced equivalent or enhanced antibody breadth, neutralization potencies, T-cell responses, and targeting of conserved RBD epitopes. In addition, mRNA-encoded mosaic-8 vaccines elicited more balanced IgG subclass profiles and increased Fcγ receptor–binding IgGs, consistent with potentially superior Fc effector functions. These findings demonstrate successful translation of mosaic-8 RBD-NPs into mRNA/EABR-mRNA vaccines, enabling scalable manufacturing and improving protection against future sarbecovirus outbreaks. Finally, our newly developed technique, Systems Serology–Polyclonal Epitope Mapping (SySPEM), revealed distinct IgG-subclass-specific epitope signatures across mRNA, EABR-mRNA, and protein vaccines, demonstrating that the mode of antigen display can shape epitope recognition. Summary: We translated a pan-sarbecovirus RBD vaccine from protein nanoparticles to scalable mRNA and EABR-mRNA platforms encoding RBD quartets. Compared with protein-based immunogens, mRNA-based vaccines matched or improved antibody breadth, T-cell responses, Fc functionality, and conserved epitope targeting. A newly-developed Systems Serology–Polyclonal Epitope Mapping (SySPEM) technique revealed that antigen presentation modality shapes IgG subclass–specific epitope recognition.Keywords
All Related Versions
- Published version: Cell Reports, 45 (5), 117335.
Funding Information
- National Institutes of Health (P01-AI165075)
- National Institutes of Health (DP5OD033362)
- National Institutes of Health (1K99AI185267)
- Medical Research Council (MR/Y011910/1)
- Merkin Institute for Translational Research, California Institute of Technology
- James B. Pendleton Charitable Trust
This publication has 85 references indexed in Scilit:
- Designed mosaic nanoparticles enhance cross-reactive immune responses in miceCell, 2025
- Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animalsCell, 2024
- ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccinesCell, 2023
- Nanoparticle and virus-like particle vaccine approaches against SARS-CoV-2Journal of Microbiology, 2022
- Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodiesCell Reports, 2021
- Overcoming Symmetry Mismatch in Vaccine Nanoassembly through Spontaneous AmidationAngewandte Chemie International Edition, 2020
- T Cell ELISPOT: For the Identification of Specific Cytokine-Secreting T Cells2015
- CTL ELISPOT Assay2014
- RNA Purification – Precipitation Methods2013
- Primary structural requirements for N- and O-glycosylation of yeast mannoproteinsBiochimica et Biophysica Acta (BBA) - General Subjects, 1984